ZWZhenru Wu

Zhenru Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhenru Wu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nakagami Statistics-Based Parametric Thermoacoustic Imaging for Assessment of Liver Microwave Ablation

    by Ling Song, Lian Feng, Jieni Song, Wanting Yang, Zhenru Wu, Wenwu Ling, Lin Huang, Yan Luo

    Thermal ablation is an effective treatment for primary liver cancer, but intraoperative assessment of ablation efficacy remains a clinical challenge. Microwave-induced thermoacoustic imaging (TAI) offers high tissue contrast based on dielectric properties, whereas conventional delay-and-sum reconstruction often yields limited contrast between ablated and normal tissue. To improve the contrast, we present a post-processing parametric imaging method that applies Nakagami statistics to thermoacoustic signal envelopes. The Nakagami shape parameter m is sensitive to thermal-ablation-induced alterations in tissue microstructural features. This work represents a new attempt to extract parametric images from thermoacoustic signal envelopes for intraoperative ablation assessment. In vitro and in vivo experiments were conducted to evaluate this Nakagami-based approach. Compared with conventional TAI, Nakagami images exhibited markedly improved contrast between the ablation zone and normal tissue. Quantitative analysis using pathological images as the gold standard demonstrated higher accuracy for Nakagami-based TAI across all measurements: 91.08% vs. 85.22% (in vitro diameter), 86.76% vs. 74.50% (in vitro area), 85.44% vs. 76.52% (in vivo diameter), and 79.22% vs. 72.72% (in vivo area). These findings suggest that Nakagami statistics-based TAI improves ablation zone characterization by capturing tissue microstructural information, showing potential as a tool for intraoperative assessment of liver ablation efficacy.

  • Open Access

    LPCAT1 and MRPL9 Promote Hepatocellular Carcinoma Progression via AKT Phosphorylation and Define a Mitochondrial Prognostic Model

    by Hui Yang, Ziqi Zhu, Hanwen Zhu, Nanjing Li, Sinian Zheng, Ling Hu, Zhenru Wu, Yujun Shi

    Background/Objectives: Mitochondrial dysfunction plays a critical role in hepatocellular carcinoma (HCC) progression. This study aimed to identify mitochondrial-related prognostic genes and elucidate their functional mechanisms in HCC. Methods: Mitochondrial-related prognostic genes were screened from the TCGA and ICGC-LIHC cohorts. A prognostic risk model was constructed and validated in three external cohorts. Immunotherapy sensitivity between high- and low-risk groups was assessed using somatic mutation and immune infiltration analyses. Underlying molecular mechanisms were further validated through in vitro experiments in HCC cell lines. Results: Transcriptome analysis identified 15 mitochondrial-related prognostic genes, from which 10 candidates were refined using LASSO regression. Among them, LPCAT1 and MRPL9 were significantly associated with overall survival. The 2-MRG model (comprising LPCAT1 and MRPL9) demonstrated superior prognostic accuracy and better survival stratification across both internal and external cohorts. Functional enrichment analysis revealed significant metabolic dysfunction in the high-risk group. The high-risk group also exhibited a significantly higher tumor mutation burden and an enhanced predicted responsiveness to immunotherapy. In vitro, knockdown of MRPL9 or LPCAT1 inhibited the proliferation and migration of HCC cells by inducing G1/S arrest and G2/M arrest, respectively. Moreover, they also suppressed the AKT phosphorylation. Conclusions: We developed a robust 2-MRG prognostic model based on LPCAT1 and MRPL9 that effectively predicts HCC outcomes and supports individualized therapeutic decision-making. Both genes promote HCC progression by modulating the AKT phosphorylation and cell-cycle checkpoints, highlighting their potential as therapeutic targets.


  • Open Access

    Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma

    by Chenhao Jiang, Zijian Liu, Jingsheng Yuan, Zhenru Wu, Lingxiang Kong, Jiayin Yang, Tao Lv

    Hepatocellular carcinoma (HCC) remains a global health challenge with a low early diagnosis rate and high mortality. The Rab GTPase (RAB) family plays an essential role in the occurrence and progression of HCC. Nonetheless, a comprehensive and systematic investigation of the RAB family has yet to be performed in HCC. We comprehensively assessed the expression landscape and prognostic significance of the RAB family in HCC and systematically correlated these RAB family genes with tumor microenvironment (TME) characteristics. Then, three RAB subtypes with distinct TME characteristics were determined. Using a machine learning algorithm, we further established a RAB score to quantify TME features and immune responses of individual tumors. Moreover, to better evaluate patient prognosis, we established a RAB risk score as an independent prognostic factor for patients with HCC. The risk models were validated in independent HCC cohorts and distinct HCC subgroups, and their complementary advantages guided clinical practice. Furthermore, we further confirmed that the knockdown of RAB13, a pivotal gene in risk models, suppressed HCC cell proliferation and metastasis by inhibiting the PI3K/AKT signaling pathway, CDK1/CDK4 expression, and epithelial-mesenchymal transition. In addition, RAB13 inhibited the activation of JAK2/STAT3 signaling and the expression of IRF1/IRF4. More importantly, we confirmed that RAB13 knockdown enhanced GPX4-dependent ferroptosis vulnerability, highlighting RAB13 as a potential therapeutic target. Overall, this work revealed that the RAB family played an integral role in forming HCC heterogeneity and complexity. RAB family-based integrative analysis contributed to enhancing our understanding of the TME and guided more effective immunotherapy and prognostic evaluation.


  • Open Access

    Comprehensive Molecular Analysis Identified an SRSF Family-Based Score for Prognosis and Therapy Efficiency Prediction in Hepatocellular Carcinoma

    by Jingsheng Yuan, Zijian Liu, Zhenru Wu, Jiayin Yang, Tao Lv

    The serine/arginine-rich splicing factors (SRSF)-mediated alternative splicing plays an essential role in the occurrence and progression of hepatocellular carcinoma (HCC). However, the SRSF-based signature that can predict the prognosis and therapy efficiency is yet to be investigated in HCC. Here, we comprehensively assessed the landscape and prognostic significance of the SRSF family genes in HCC. Then, we screened the SRSF family-related genes for signature construction and explored their biological characteristics. We further established an SRSF score consisting of 18 SRSF-associated genes and evaluated its correlation with prognosis and drug sensitivity in HCC. The predictive power of the SRSF score was validated in independent HCC cohorts and different HCC subgroups. Moreover, we further investigated that knockdown of SRSF11, a pivotal gene in the SRSF score, inhibited CDK1-dependent proliferation and enhanced the drug sensitivity of HCC cells. Overall, our study identified a novel SRSF family-based predictive model, and we demonstrated that SRSF11 is a promising therapeutic target for HCC, which enhances our understanding of the SRSF family genes and provides valuable insights into the clinical treatment and molecular mechanisms of HCC.


  • Open Access

    Double-Negative α-Fetoprotein and Carbohydrate Antigen 19-9 Predict a Good Prognosis in Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis

    by Xiaoyun Zhang, Yongjie Zhou, Zhenru Wu, Wei Peng, Chuan Li, Lvnan Yan, Jiayin Yang, Tianfu Wen

    INTRODUCTION: Carbohydrate antigen 19-9 (CA19-9) and α-fetoprotein (AFP) are routinely tested in patients with liver malignancies before surgery. However, few reports have explored the relevance of the expression pattern of these 2 tumor markers regarding the prognosis of intrahepatic cholangiocarcinoma (ICC). We herein combined these 2 tumor markers to investigate the influence on ICC malignancy and patient prognosis. METHODS: From March 2009 to December 2019, 519 consecutive patients with newly diagnosed ICC who underwent R0 resection were enrolled and followed. The relationships between clinicopathological parameters and these 2 tumor markers were analyzed. Propensity score matching was used to eliminate the baseline differences. RESULTS: A lower proportion of patients with double-negative AFP and CA19-9 had advanced tumor-node-metastasis stage, larger tumor diameter, multiple tumors, lymph node metastasis, microvascular invasion, and perineural invasion. With propensity score matching, patients were divided into double-negative and non-double-negative groups, with 128 patients in each group, and the 5-year recurrence-free survival and overall survival rates were 33.8 vs 15.2 (P < 0.001) and 45.3 vs 19.0, respectively (P < 0.001). In the multivariate Cox analyses, double negativity for the 2 tumor markers was an independent factor for recurrence-free survival (hazard ratios, 0.578; 95% CI, 0.442–0.755, P < 0.001) and overall survival (hazard ratios, 0.567; 95% CI, 0.434–0.741, P < 0.001). DISCUSSION: Double negativity for CA19-9 and AFP indicated less invasive tumor characteristics in patients with ICC. Patients with double-negative tumor markers achieved better outcomes than those with non-double-negative markers, which is meaningful for prognostic counseling and therapeutic triage.